v3.19.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenue:    
Grant and licensing revenue $ 701,062 $ 752,527
Operating expenses:    
Research and development 3,172,247 2,872,950
General and administrative 3,347,601 1,780,339
Change in fair value of contingent consideration 114,290 11,118
Total operating expenses 6,634,138 4,664,407
Loss from operations (5,933,076) (3,911,880)
Interest income 150,852 3,633
Other income, net 8,321 175,020
Total non-operating income, net 159,173 178,653
Net loss before income taxes (5,773,903) (3,733,227)
Income tax expense (benefit) 45,178 (205,000)
Net loss (5,819,081) (3,528,227)
Net loss - non-controlling interest (103,605) (206,461)
Net loss attributable to Heat Biologics, Inc. $ (5,715,476) $ (3,321,766)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.17) $ (0.71)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 33,225,164 4,709,553
Other comprehensive loss:    
Net loss $ (5,819,081) $ (3,528,227)
Unrealized (loss) gain on foreign currency translation (8,189) 21,325
Total other comprehensive loss (5,827,270) (3,506,902)
Comprehensive loss attributable to non-controlling interest (103,605) (206,461)
Comprehensive loss $ (5,723,665) $ (3,300,441)

Source